Accumulate Aurobindo Pharma; target of Rs 635: Prabhudas Lilladher

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Prabhudas Lilladher's research report on Aurobindo Pharma

Aurobindo Pharma’s (ARBP) operating performance continued to remain weak in Q1FY23, given cost headwinds. We believe cost pressures to remain in near term and margin trajectory should improve from H2FY23. However, pick up in US sales hinge on timely niche approvals along with stabilization of pricing pressure in base business. ARBP has multiple growth drivers in place with investments in vaccines, injectables, biosimilars and PLI, which are expected to be reflected from FY24. At CMP, stock is trading at 11.4x FY24E P/E. We broadly maintained our estimates.

Outlook

We recommend ‘Accumulate’ with TP of Rs635 .

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Aurobindo Pharma - 160822 - prabhu